Clinical Trial Update: An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

View source ↗

Summary

Observational study assessing safety and efficacy of cetuximab added to FOLFIRI or FOLFOX as first-line therapy for KRAS wild-type metastatic colorectal cancer.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Colorectal Neoplasms | Status: TERMINATED